Navigation Links
Acquisition of Devices, Methods and Intellectual Property Support Leadership Position in Regenerative Therapies
Date:7/22/2013

AUSTIN, Texas, July 22, 2013 /PRNewswire/ -- On Wednesday, July 17th, Celling Biosciences made an asset acquisition of devices, proprietary methods and intellectual property from Orogen Biosciences.  Orogen, based out of Sarasota, Florida, was an early innovator in processing platelet rich plasma (PRP) and concentrating growth factors and cytokines to optimize the most effective and efficient methods for providing therapeutic treatments with a patient's own tissue.   With this acquisition, Celling is furthering its position as a leader of point of care, autologous cell therapy. 

Celling is focused on the three pillars of regenerative medicine (cells, substrates, and signals) known to enhance the environment for tissue repair, regeneration, and revascularization.  The devices (OPC and ACE) and methods from Orogen provide physicians with access to a patient's own growth factors and proteins to support the healing cascade.  There is a growing body of evidence in the literature of the role growth factors play in optimizing the healing in multiple pathologies across medicine.  The OPC device allows physicians to process autologous plasma at the point of care to deliver concentrated growth factors when compared to currently marketed options.  The ACE device is a unique technology that produces an enriched preparation of growth factors without the presence of white blood cells, red blood cells or platelets. 

Additionally, Celling has acquired methods and devices for delivering allogeneic products to the veterinary market. Based on the short and long term success of these products in treating horses and canines in soft tissue repair, Celling will be well positioned to penetrate the veterinary market which is leading human efforts into the emerging market of regenerative medicine.   

Celling has begun the process of transitioning Oro
'/>"/>

SOURCE Celling Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. DTx to Introduce Data Acquisition Control & Robotic Instrument (DACRI) at Clinical Lab Expo in Houston, TX.
2. Techne Corporation Announces Acquisition Agreement
3. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
4. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
5. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
6. bioRASI Completes Acquisition of Ukrainian CRO
7. BGI-Shenzhen Completes Acquisition of Complete Genomics
8. Biotrial, a Leading Provider of Drug Development Services, Has Completed its Acquisition of Warnex Bioanalytical Services Division
9. Inflamax Research Introduces Electronic Patient Data Acquisition Tabletâ„¢ (ePDAT)â„¢ for Real-Time PRO Data Collection
10. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
11. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 China Cord Blood Corporation (NYSE: CO) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has filed its Annual Report ... Commission. The filed Form 20-F includes audited financial statements ... Form 20-F can be accessed by visiting the U.S. ...
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... Dallas, Texas (PRWEB) , ... July 30, 2015 , ... ... professional and in-depth study on the current state of the global Propanol market with ... are Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal ...
(Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... 17 , - New ... Short-Term Mortality Compared to Previous Treatments , ... positive final results,from a Phase II trial of its ... acute myeloid leukaemia (AML). In the,trial, elacytarabine showed statistically ...
... , SHANGHAI, June 17 ... ("China-Biotics", "the Company"), a leading Chinese firm,specializing in ... products, today announced it will join the Russell,3000(R) ... its comprehensive set of U.S. and global equity ...
... (Nasdaq: PRXL ) announced today it will be ... Boston. James Winschel, Senior Vice President & Chief Financial ... 10:15 a.m. EDT on Tuesday, June 23, 2009. ... be available through the "Investor Relations - Upcoming Events" ...
Cached Biology Technology:Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7China-Biotics, Inc. to Join Russell 3000 Index 2China-Biotics, Inc. to Join Russell 3000 Index 3PAREXEL International to Present at the Wachovia Equity Conference 2
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/2/2015)... July 2, 2015 Fingerprint Cards has ... FPC1145 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... will be used by smartphone manufacturers in Asia ... in the communicated revenue guidance of approximately 2,200 MSEK for ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... ability to promote agricultural and conservation successes in the ... scientists, understanding of how plants adapt to local climate. ... study in the Oct. 7, 2011 issue of ... adaptations to local climate. The National Science Foundation ...
... Agrarian Research (IVIA, Spain) have created a machine that ... segments according to their quality and another that helps ... use computer vision to automatically inspect the fruits. ... dark rooms with the help of ultraviolet light that ...
... York Stem Cell Foundation (NYSCF) announced today that a British ... first recipient of The New York Stem Cell Foundation ... annually for extraordinary achievement in translational stem cell research. ... Director of the London Project to Cure Blindness and Professor ...
Cached Biology News:Oranges and mandarins are inspected using artificial vision 2Oranges and mandarins are inspected using artificial vision 3Professor Peter J. Coffey's stem cell therapy for Age-Related Macular Degeneration expected to begin clinical trials in 2012 2Professor Peter J. Coffey's stem cell therapy for Age-Related Macular Degeneration expected to begin clinical trials in 2012 3
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Biology Products: